Atlas Trials

Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

Clinical trial NCT04489433 · NO_LONGER_AVAILABLE

Trial details

NCT number
NCT04489433
Sponsor
Novartis Pharmaceuticals
Status
NO_LONGER_AVAILABLE
Study type
EXPANDED_ACCESS
Melanoma

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.